Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and Efficacy of rFVIII in Chinese Patients with Hemophilia A
NCT02930317Phase 3Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Aug 2016
- Primary completion
- Oct 2017
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, open-label trial of moroctocog alfa in hemophilia A (2 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Recovery rate of rFVIII activity and Investigator Hemostatic Efficacy Assessment. Status: unknown.
02
Drugs
moroctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT02930317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02930317.